PDIA3

Across TCGA pan-cancer cohorts, PDIA3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PDIA3 data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher PDIA3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PDIA3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCS, UCEC, and KIRC are the cancer types where PDIA3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	DFS	Median	IV	0.132	0.718	.002	36	view →
UCEC	DFS	Median	All	1.000	0.616	.002	36	view →
KIRC	OS	Median	All	0.057	0.881	<.001	12	view →
COAD	OS	Median	II,III,IV	0.168	0.788	.005	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PDIA3–UCS (DFS)

Open the UCS breakdown →